Literature DB >> 14985764

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Matthew Stremlau1, Christopher M Owens, Michel J Perron, Michael Kiessling, Patrick Autissier, Joseph Sodroski.   

Abstract

Host cell barriers to the early phase of immunodeficiency virus replication explain the current distribution of these viruses among human and non-human primate species. Human immunodeficiency virus type 1 (HIV-1), the cause of acquired immunodeficiency syndrome (AIDS) in humans, efficiently enters the cells of Old World monkeys but encounters a block before reverse transcription. This species-specific restriction acts on the incoming HIV-1 capsid and is mediated by a dominant repressive factor. Here we identify TRIM5alpha, a component of cytoplasmic bodies, as the blocking factor. HIV-1 infection is restricted more efficiently by rhesus monkey TRIM5alpha than by human TRIM5alpha. The simian immunodeficiency virus, which naturally infects Old World monkeys, is less susceptible to the TRIM5alpha-mediated block than is HIV-1, and this difference in susceptibility is due to the viral capsid. The early block to HIV-1 infection in monkey cells is relieved by interference with TRIM5alpha expression. Our studies identify TRIM5alpha as a species-specific mediator of innate cellular resistance to HIV-1 and reveal host cell components that modulate the uncoating of a retroviral capsid.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985764     DOI: 10.1038/nature02343

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  983 in total

1.  Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms.

Authors:  Emilie Battivelli; Julie Migraine; Denise Lecossier; Saori Matsuoka; Danielle Perez-Bercoff; Sentob Saragosti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  In defense of the cell: TRIM5alpha interception of mammalian retroviruses.

Authors:  Kyeongeun Lee; Vineet N KewalRamani
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-13       Impact factor: 11.205

Review 3.  Retroviruses under editing crossfire: a second member of the human APOBEC3 family is a Vif-blockable innate antiretroviral factor.

Authors:  Didier Trono
Journal:  EMBO Rep       Date:  2004-07       Impact factor: 8.807

4.  Biography of Nancy Hopkins.

Authors:  Christen Brownlee
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-24       Impact factor: 11.205

Review 5.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

Review 6.  Molecular evolution of the antiretroviral TRIM5 gene.

Authors:  Welkin E Johnson; Sara L Sawyer
Journal:  Immunogenetics       Date:  2009-02-24       Impact factor: 2.846

7.  Characterisation of a cluster of TRIM-B30.2 genes in the chicken MHC B locus.

Authors:  Thomas Ruby; Bertrand Bed'Hom; Hakan Wittzell; Véronique Morin; Anne Oudin; Rima Zoorob
Journal:  Immunogenetics       Date:  2005-03-03       Impact factor: 2.846

8.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Longitudinal analysis of monocyte/macrophage infection in simian immunodeficiency virus-infected, CD8+ T-cell-depleted macaques that develop lentiviral encephalitis.

Authors:  Stephanie J Bissel; Guoji Wang; Anita M Trichel; Michael Murphey-Corb; Clayton A Wiley
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

10.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.